Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative

Singh, Deependra; Vignat, Jérôme; Lorenzoni, Valentina; Eslahi, Marzieh; Ginsburg, Ophira; Lauby‐Secretan, Béatrice; Arbyn, Marc; Basu, Partha; Bray, Freddie; Vaccarella, Salvatore

doi:10.1016/s2214-109x(22)00501-0

Cited by 440 publications

(353 citation statements)

References 35 publications

Supporting

Mentioning

226

Contrasting

Unclassified

Order By: Relevance

“…The highest incidence rates are observed in Eastern Asia, South Central Asia, and Central and Eastern Europe. Besides, OC is the eighth most common malignancy among women [ 11 ], (Fig. 1 ).…”

Section: Introductionmentioning

confidence: 99%

Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction

et al. 2023

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are an important component of the tumor microenvironment (TME) and have been linked to immunosuppression and poor prognosis. TAMs have been shown to be harmful in ovarian cancer (OC), with a positive correlation between their high levels of tumors and poor overall patient survival. These cells are crucial in the progression and chemoresistance of OC. The primary pro-tumoral role of TAMs is the release of cytokines, chemokines, enzymes, and exosomes that directly enhance the invasion potential and chemoresistance of OC by activating their pro-survival signalling pathways. TAMs play a crucial role in the metastasis of OC in the peritoneum and ascities by assisting in spheroid formation and cancer cell adhesion to the metastatic regions. Furthermore, TAMs interact with tumor protein p53 (TP53), exosomes, and other immune cells, such as stem cells and cancer-associated fibroblasts (CAFs) to support the progression and metastasis of OC. In this review we revisit development, functions and interactions of TAMs in the TME of OC patients to highlight and shed light on challenges and excitement down the road.

show abstract

Section: Introductionmentioning

confidence: 99%

Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In 2020, over 600,000 women were diagnosed with cervical cancer globally, while 300,000 died from it [ 1 ]. In a call to eliminate cervical cancer, the World Health Organization (WHO) has launched the 90-70-90 target for countries to achieve by 2030: (1) 90% of girls fully vaccinated against human papillomavirus (HPV) by the age of 15; (2) 70% of women screened with a high-performance test by the age of 35 and 45; (3) 90% of women identified with cervical precancer and cancer received treatment [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore

Chua

Lim

et al. 2023

Cancers

View full text Add to dashboard Cite

Human papillomavirus (HPV) partial genotyping (PGT) identifies HPV16 and HPV18 individually, alongside 12 other high-risk HPV genotypes (hrHPV) collectively. HPV extended genotyping (XGT) identifies four additional hrHPV individually (HPV31, 45, 51, and 52), and reports the remaining eight in three groups (HPV33|58; 56|59|66; 35|39|68). Quality-adjusted life years (QALY), health care resource use, and costs of XGT were compared to PGT for cervical cancer screening in Singapore using DICE simulation. Women with one of the three hrHPV identified by XGT (HPV35|39|68; 56|59|66; 51), and atypical squamous cells of undetermined significance (ASCUS) on cytology, are recalled for a repeat screening in one year, instead of undergoing an immediate colposcopy with PGT. At the repeat screening, the colposcopy is performed only for persistent same-genotype infections in XGT, while with PGT, all the women with persistent HPV have a colposcopy. Screening 500,122 women, aged 30–69, with XGT, provided an incremental cost-effectiveness ratio (ICER) versus PGT of SGD 16,370/QALY, with 7130 (19.4%) fewer colposcopies, 6027 (7.0%) fewer cytology tests, 9787 (1.6%) fewer clinic consultations, yet 2446 (0.5%) more HPV tests. The XGT ICER remains well below SGD 100,000 in sensitivity analyses, (-SGD 17,736/QALY to SGD 50,474/QALY). XGT is cost-effective compared to PGT, utilizes fewer resources, and provides a risk-based approach as the primary cervical cancer screening method.

show abstract

“…6,7 The incidence of cervical cancer in countries with a low Human Development Index (HDI) is 3 times higher than that of high-HDI countries, and mortality rates are 6 times higher than those in countries with high HDI. 8 Further, a major effect on mortality was observed, particularly in the United States, where the cervical cancer death rate is 2-fold higher among women residing in high-vs low-poverty areas. 6 The results presented by Chung et al, 1 in accordance with those of other authors, including ours, demonstrate the current alarming inadequacy of CCS in patients with SLE.…”

Section: To the Editormentioning

confidence: 99%

Cervical Cancer Screening Is a Highly Neglected Procedure Among Women With Systemic Lupus Erythematosus

Cintra¹,

Araújo²,

Dib

et al. 2023

J Rheumatol

View full text Add to dashboard Cite

show abstract

Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative

Cited by 440 publications

References 35 publications

Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction

Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction

Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore

Cervical Cancer Screening Is a Highly Neglected Procedure Among Women With Systemic Lupus Erythematosus

Contact Info

Product

Resources

About